Yamane Maya L M, Belsito Donald V, Glass Lora R Dagi
Vagelos College of Physicians & Surgeons, Columbia University , New York , NY , USA.
Department of Dermatology, Columbia University Irving Medical Center , New York , NY , USA.
Orbit. 2019 Oct;38(5):390-394. doi: 10.1080/01676830.2018.1553190. Epub 2019 Jan 10.
Dupilumab is a monoclonal antibody used to treat atopic dermatitis. Worsening of atopic dermatitis and conjunctivitis following dupilumab use are reported adverse effects; however, there is little reported on the nature and mechanism of these complications. Here, we describe two patients with chronic atopic dermatitis who developed new or severely worsened periocular dermatitis, believed to be a side effect of dupilumab injections, and resolution after its discontinuation. We explore the possibility of dupilumab-induced suppression of Th2 mediated inflammation and upregulation of Th1 and IFNγ mediated inflammation as a possible mechanism.
度普利尤单抗是一种用于治疗特应性皮炎的单克隆抗体。使用度普利尤单抗后特应性皮炎和结膜炎恶化是报告的不良反应；然而，关于这些并发症的性质和机制报道甚少。在此，我们描述了两名慢性特应性皮炎患者，他们出现了新的或严重恶化的眼周皮炎，据信这是度普利尤单抗注射的副作用，停药后症状缓解。我们探讨了度普利尤单抗诱导Th2介导的炎症受抑制以及Th1和IFNγ介导的炎症上调作为一种可能机制的可能性。
